Your browser is no longer supported. Please, upgrade your browser.
Settings
MNTA Momenta Pharmaceuticals, Inc. daily Stock Chart
MNTA [NASD]
Momenta Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.42 Insider Own1.70% Shs Outstand76.11M Perf Week-5.14%
Market Cap1.12B Forward P/E- EPS next Y-0.65 Insider Trans-3.20% Shs Float69.03M Perf Month5.36%
Income-28.80M PEG- EPS next Q-0.49 Inst Own92.80% Short Float5.14% Perf Quarter-7.23%
Sales116.40M P/S9.64 EPS this Y76.80% Inst Trans4.44% Short Ratio4.50 Perf Half Y4.61%
Book/sh5.31 P/B2.78 EPS next Y54.50% ROA-6.30% Target Price16.14 Perf Year35.32%
Cash/sh5.70 P/C2.59 EPS next 5Y- ROE-8.20% 52W Range9.66 - 19.90 Perf YTD-1.99%
Dividend- P/FCF21.93 EPS past 5Y-15.80% ROI-20.10% 52W High-25.88% Beta1.74
Dividend %- Quick Ratio4.10 Sales past 5Y-17.30% Gross Margin- 52W Low52.69% ATR0.56
Employees290 Current Ratio4.10 Sales Q/Q33.70% Oper. Margin-71.20% RSI (14)47.25 Volatility4.08% 3.86%
OptionableYes Debt/Eq0.00 EPS Q/Q-29.60% Profit Margin-24.70% Rel Volume0.74 Prev Close15.00
ShortableYes LT Debt/Eq0.00 EarningsMay 02 BMO Payout- Avg Volume788.63K Price14.75
Recom2.70 SMA20-4.56% SMA503.38% SMA2005.49% Volume584,109 Change-1.67%
May-22-17Downgrade Barclays Overweight → Equal Weight $20 → $17
Feb-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Jan-31-17Reiterated Barclays Overweight $19 → $20
Nov-22-16Initiated Aegis Capital Hold
Oct-11-16Upgrade Barclays Equal Weight → Overweight $13 → $19
Sep-07-16Downgrade Maxim Group Hold → Sell $6
Jun-06-16Initiated Goldman Neutral $14
Jan-08-16Upgrade Maxim Group Sell → Hold
Nov-13-15Initiated JP Morgan Overweight
Aug-06-15Downgrade Goldman Buy → Neutral
Jun-19-15Reiterated Stifel Buy $26 → $29
Jun-19-15Reiterated Brean Capital Buy $25 → $31
Jun-04-15Initiated Stifel Buy $26
Apr-17-15Reiterated Leerink Partners Outperform $16 → $24
Apr-17-15Reiterated Brean Capital Buy $15 → $25
Feb-18-15Reiterated UBS Buy $18 → $15
Jan-23-15Downgrade Maxim Group Buy → Sell $17 → $7
Jan-08-15Initiated Brean Capital Buy $15
Jun-05-14Resumed Maxim Group Buy $24 → $17
May-09-14Initiated Maxim Group Buy $24
May-10-17 04:05PM  UPDATE -- Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences GlobeNewswire -5.31%
08:00AM  Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences GlobeNewswire
May-04-17 03:25PM  Edited Transcript of MNTA earnings conference call or presentation 2-May-17 2:00pm GMT Thomson Reuters StreetEvents
May-03-17 04:19PM  Momenta Pharmaceuticals, Inc. Looks for Some Momentum Motley Fool
10:32AM  Momenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat Zacks
May-02-17 05:23PM  Momenta Pharmaceuticals, Inc. Value Analysis (NASDAQ:MNTA) : May 2, 2017 Capital Cube +7.14%
08:07AM  Momenta reports 1Q loss Associated Press
08:00AM  Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results GlobeNewswire
07:55AM  Investor Network: Momenta Pharmaceuticals, Inc. to Host Earnings Call Accesswire
May-01-17 08:09AM  Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : May 1, 2017 Capital Cube
Apr-26-17 08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 42nd Annual Health Care Conference GlobeNewswire
Apr-18-17 08:00AM  Momenta Pharmaceuticals Announces Date of First Quarter 2017 Financial Results Conference Call and Webcast GlobeNewswire
Mar-29-17 07:00AM  Why Is Momenta (MNTA) Down 9.6% Since the Last Earnings Report? Zacks
07:00AM  Why Is Momenta (MNTA) Down 9.6% Since the Last Earnings Report? at Investopedia
Mar-24-17 07:01PM  Lifshitz & Miller LLP Announces Investigation of Aratana Therapeutics, Inc., FXCM Inc., Innocoll Holdings plc, Momenta Pharmaceuticals, Inc., Omnicom Group Inc., Perrigo Company plc, Santander Consumer USA Holdings Inc. and The Interpublic Group of Companies, Inc. PR Newswire
Mar-17-17 04:06PM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fina
Mar-08-17 07:52AM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Mar-07-17 11:09AM  INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Momenta Pharmaceuticals, Inc. -- MNTA PR Newswire
Mar-02-17 01:04PM  MOMENTA PHARMACEUTICALS INC Financials
Feb-28-17 03:29PM  FDA warns Pfizer over contaminated drugs at Kansas plant Reuters
08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-24-17 04:56PM  MOMENTA PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
11:28AM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Momenta Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
10:30AM  Glancy Prongay & Murray LLP Commences Investigation on Behalf of Momenta Pharmaceuticals, Inc. Investors Business Wire
Feb-23-17 03:58PM  Momenta Pharmaceuticals, Inc. Earnings Take a Back Seat Motley Fool
03:58PM  Momenta Pharmaceuticals, Inc. Earnings Take a Back Seat at Motley Fool
09:45AM  [2/23] Today's Top 10 Long/Short Estimize Signal Scores
08:59AM  Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca Zacks
Feb-22-17 03:13PM  Momenta Tops Q4 Earnings, Shares Down on Warning Letter -5.92%
02:33PM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Momenta Pharmaceuticals, Inc., and Encourages Investors to Contact the Firm Business Wire
02:02PM  Manufacturing Delay Of Generic Drug From Pfizer Inc. (PFE) A Relief For Teva Pharmaceutical Industries Ltd (ADR) (TEVA) at Insider Monkey
12:16PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Momenta Pharmaceuticals, Inc. -- MNTA Business Wire
11:05AM  Momenta 4Q Net 60 Cents a Share at Investopedia
10:30AM  INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Momenta Pharmaceuticals, Inc. Investors Business Wire
10:24AM  Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Momenta Pharmaceuticals, Inc. (MNTA) PR Newswire
08:18AM  Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : February 22, 2017
08:03AM  Analysts' Actions -- Discovery, First Solar, Momenta, VF Corp. and More
Feb-21-17 04:45PM  Why Momenta Pharmaceuticals, Northern Dynasty Minerals, and Unilever Slumped Today at Motley Fool -15.53%
04:27PM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Momenta Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
04:22PM  Edited Transcript of MNTA earnings conference call or presentation 21-Feb-17 1:00pm GMT
01:37PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Momenta Pharmaceuticals, Inc. - MNTA PR Newswire
12:37PM  Momenta, Pfizer Give Teva Pharma Breathing Room On Generic MS Drug
12:26PM  Why Momenta Pharmaceuticals, Inc. Shares Got Crushed Today at Motley Fool
11:35AM  Momenta shares plunge after supplier receives warning letter from FDA on multiple sclerosis drug at CNBC
10:20AM  Momenta Pharma's Supply Partner Gets FDA Warning at Investopedia
10:09AM  Sarepta Leads Biotech Movers on Voucher Deal News
09:35AM  Momenta beats Street 4Q forecasts
07:07AM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
07:07AM  Q4 2016 Momenta Pharmaceuticals Inc Earnings Release - Before Market Open
07:00AM  Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results GlobeNewswire
Feb-20-17 06:52AM  Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS
Feb-17-17 06:41PM  Momenta Pharma shares halted as drug application hits speed bump at MarketWatch
06:05PM  Momenta Pharmaceuticals Announces Time Change for Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast GlobeNewswire
06:00PM  Momenta Pharmaceuticals Announces FDA Warning Letter to Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer GlobeNewswire
08:00AM  Momenta Pharmaceuticals Announces HSR Clearance for Collaboration and License Agreement with CSL GlobeNewswire
Feb-14-17 09:30AM  The Zacks Analyst Blog Highlights: MidWestOne Financial Group, Brooks Automation, Cross Country Healthcare, Francesca's Holdings and Momenta Pharmaceuticals
Feb-13-17 09:14AM  Forget Gilead, Buy These 5 Biotech Stocks Instead
08:53AM  5 Stocks to Buy as Trump Chalks Out 'Phenomenal' Tax Plan
07:02AM  Teva Pharm Q4 profit, revenue beat expectations Reuters
Feb-10-17 03:24AM  Can The Uptrend Continue for Momenta Pharmaceuticals (MNTA)?
Feb-07-17 08:00AM  Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast GlobeNewswire
Feb-01-17 10:11AM  Momenta Says District of Delaware Invalidates Teva's MS Drug
09:45AM  Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on AEterna Zentaris and Momenta Pharmaceuticals Accesswire
08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the Leerink Partners 6th Annual Global Healthcare Conference GlobeNewswire
Jan-31-17 06:30PM  Why Momenta Pharmaceuticals, Ally Financial, and Thermo Fisher Scientific Jumped Today at Motley Fool +25.17%
01:03PM  Why Momenta Pharmaceuticals, Inc. Stock Skyrocketed Higher Today at Motley Fool
11:58AM  Instant Analysis: Is Teva Pharmaceutical Industries a Buy on the Dip? at Motley Fool
11:16AM  Mylan's Shares Rise Despite FTC Investigation
09:27AM  Premarket Biotech Movers: Mylan, Momenta Pharmaceuticals, Seres Therapeutics
08:00AM  Momenta Pharmaceuticals Announces District Court Decision to Invalidate Teva Pharmaceuticals Patents in COPAXONE® (glatiramer acetate injection) 40 mg/mL Litigation GlobeNewswire
Jan-24-17 10:33AM  Momenta Pharmaceuticals, Inc. Value Analysis (NASDAQ:MNTA) : January 24, 2017
Jan-23-17 08:24AM  Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : January 23, 2017
Jan-13-17 09:06AM  Mylans Recent Commercial and Product Developments
Jan-09-17 09:15AM  Biotech Industry Off to a Strong Start in 2017 Latest Reports on Sarepta Therapeutics and Momenta Pharmaceuticals Accesswire
07:39AM  Teva Falls on Disappointing 2017 Sales & Earnings Guidance
Jan-06-17 06:44PM  Momenta (MNTA) to Receive $50M Under CSL Collaboration +5.81%
02:00PM  Cambridge's Momenta sees shares jump on $50M drug development deal at bizjournals.com
08:23AM  Momenta stock rises 4% on corporate update at MarketWatch
08:09AM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financia
08:00AM  Momenta Provides Year-End 2016 Corporate Update GlobeNewswire
Jan-05-17 04:11PM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
04:01PM  Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors GlobeNewswire
02:40PM  Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference at bizjournals.com
Jan-03-17 08:04AM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the 35th Annual J. P. Morgan Healthcare Conference GlobeNewswire
Dec-21-16 04:44PM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Dec-16-16 05:13PM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
Dec-07-16 09:05AM  Teva Copaxone EU Label to Omit Pregnancy Contraindication
05:57AM  Is Momenta Pharmaceuticals, Inc. (MNTA) A Good Stock To Buy? at Insider Monkey
Nov-30-16 05:18PM  Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar
11:17AM  What Happens When Your Biotech Stock Faces Generic Competition Lawsuits? at Motley Fool
10:10AM  Company News for November 30, 2016
09:58AM  Momenta/Shire's Humira Biosimilar Meets Study Objective
Nov-29-16 09:09AM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
08:23AM  Momenta stock jumps nearly 10% on positive late-stage results for Humira biosimilar at MarketWatch
08:00AM  Momenta Pharmaceuticals Announces Positive Top-Line Phase 3 Results for M923, a Proposed HUMIRA® (adalimumab) Biosimilar GlobeNewswire
Nov-23-16 01:13PM  ETFs with exposure to Momenta Pharmaceuticals, Inc. : November 23, 2016
Nov-22-16 05:24PM  Medtronic, Patterson Among Day's Biggest Losers, Trump Continues to Pressure Healthcare Sector -6.71%
08:09AM  Teva's Leukemia Drug Gets EU Approval in First-Line Setting
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company's novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy; M281, a fully-human monoclonal antibody that blocks the neonatal Fc receptor; and M230, a selective immunomodulator of Fc receptors candidate. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leicher BruceSVP & General CounselMay 22Sale14.8085912,713174,342May 23 02:47 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchMay 19Sale15.9082113,054489,629May 23 02:51 PM
WHEELER CRAIG APresidentMay 19Sale15.834,11665,156279,861May 23 02:49 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchMay 10Sale16.003846,144490,453May 12 02:13 PM
Leicher BruceSVP & General CounselMay 10Sale16.003475,552175,205May 12 02:14 PM
WHEELER CRAIG APresidentMay 10Sale15.771,85229,206283,977May 12 02:13 PM
WHEELER CRAIG APresidentFeb 22Sale15.515,62687,259301,365Feb 24 06:35 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchFeb 22Sale15.601,06916,676490,837Feb 24 06:24 PM
Leicher BruceSVP & General CounselFeb 22Sale15.601,05016,380175,552Feb 24 06:19 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchFeb 10Sale18.901,75633,188491,906Feb 14 05:42 PM
Leicher BruceSVP & General CounselFeb 10Sale18.901,62030,618176,602Feb 14 05:33 PM
WHEELER CRAIG APresidentFeb 10Sale18.857,088133,609306,991Feb 14 05:38 PM
Leicher BruceSVP & General CounselJan 31Sale18.005,00090,000178,222Feb 02 03:54 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchJan 09Option Exercise9.4539,647374,784493,662Jan 10 03:34 PM
Shea Richard PSVP, CFODec 15Sale15.009,799146,985119,906Dec 16 03:41 PM
Shea Richard PSVP, CFODec 09Sale15.001,45121,765129,705Dec 12 04:32 PM
WHEELER CRAIG APresidentNov 22Sale14.051,76424,784320,699Nov 23 10:52 AM
Shea Richard PSVP, CFONov 22Sale14.402273,269131,156Nov 23 10:46 AM
Roach James M.Senior VP, Development and ChiNov 22Sale14.402503,600155,381Nov 23 10:41 AM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchNov 22Sale14.402273,269454,015Nov 23 10:36 AM
Leicher BruceSVP & General CounselNov 22Sale14.402273,269182,576Nov 23 10:32 AM
WHEELER CRAIG APresidentNov 21Sale13.524,11655,648322,463Nov 23 10:52 AM
Shea Richard PSVP, CFONov 21Sale13.4574410,007131,383Nov 23 10:46 AM
Roach James M.Senior VP, Development and ChiNov 21Sale13.4584111,311155,631Nov 23 10:41 AM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchNov 21Sale13.4582111,042454,242Nov 23 10:36 AM
Leicher BruceSVP & General CounselNov 21Sale13.4580310,800182,803Nov 23 10:32 AM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchAug 22Sale12.102272,747455,063Aug 23 05:33 PM
Roach James M.Senior VP, Development and ChiAug 22Sale12.102493,013156,472Aug 23 05:30 PM
Leicher BruceSVP & General CounselAug 22Sale12.102272,747182,952Aug 23 05:28 PM
Shea Richard PSVP, CFOAug 22Sale12.102272,747132,127Aug 23 05:26 PM
WHEELER CRAIG APresidentAug 22Sale12.001,76421,168333,199Aug 23 05:05 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchAug 19Sale12.048229,897455,290Aug 23 05:33 PM
Roach James M.Senior VP, Development and ChiAug 19Sale12.0484210,138156,721Aug 23 05:30 PM
Leicher BruceSVP & General CounselAug 19Sale12.048039,668183,179Aug 23 05:28 PM
Shea Richard PSVP, CFOAug 19Sale12.047458,970132,354Aug 23 05:26 PM
WHEELER CRAIG APresidentAug 19Sale12.044,11649,536334,963Aug 23 05:05 PM
Shapiro Bennett MDirectorJun 01Option Exercise12.905,20067,0805,200Jun 08 03:55 PM
Shapiro Bennett MDirectorJun 01Sale13.005,20067,60010,834Jun 08 03:55 PM